"The first three months of 2018 have culminated in an inflection point for Jvion. Marked by immense growth, strong financial performance, and solid investor backing, Q1 2018 is a demonstration of the strong differentiation exemplified by our solution and our team. In addition to the expanding compliment of vectors including opioid addiction, we completed a successful pilot at Intermountian Healthcare, expanded at Sentara, added MD Anderson and Baylor Scott & White to our roster of impressive clients, achieved phenomenal results at Unity Point, and won the Top Innovator award from the Accenture HealthTech Innovation Challenge. We are looking forward to increased momentum and continued market expansion as we build on these great accomplishments across 2018."
– Shantanu Nigam, CEO